Sierra World Equity Review wrote that GlaxoSmithKline (NYSE: GSK) was interested in the possible acquisition of Keryx Biopharmaceuticals Inc. (Nasdaq: KERX). Shares of GlaxoSmithKline added 19 cents to close at $44.22 while Keryx stock gained 76 cents to close at $7.19.GSK